Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2953–2976 of 13,629 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Colon Cancer, Breast Cancer, Cancer of the Head and Neck
Interventions: SYN004; Biological
Lead sponsor: Synermore Biologics Co., Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: New Orleans, Louisiana • St Louis, Missouri

Conditions: Alopecia Areata
Interventions: Not listed
Lead sponsor: CorEvitas; Network
Eligibility: 12 Years to 17 Years
Enrollment: 1,500 participants
Timeline: 2024 – 2099
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Acne Vulgaris
Interventions: dapsone gel; Drug
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 9 Years to 11 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 20
States / cities: Birmingham, Alabama • Fremont, California • Northridge, California + 17 more

Conditions: Acne Vulgaris
Interventions: APS Topical Lotion, Placebo; Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 39 Years
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Miami Beach, Florida

Conditions: Atopic Dermatitis
Interventions: IMVAMUNE; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 632 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 15
States / cities: Tucson, Arizona • Hot Springs, Arkansas • Garden Grove, California + 11 more

Conditions: Breast Cancer
Interventions: Perflutren Protein-Type A Microspheres Injectable Suspension, Contrast-Enhanced Ultrasound (CEUS), Biopsy + Radioactive Seed Placement, Phone Call; Drug · Device · Procedure + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Peripheral Neuropathy
Interventions: L-glutamine; Dietary Supplement
Lead sponsor: Eastern Regional Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetic Foot Ulcer, Osteomyelitis Chronic
Interventions: Borate-base Bioactive Glass Fiber Matrix (BBGFM); Device
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions: Bevacizumab, Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 448
States / cities: Jonesboro, Arkansas • Rogers, Arkansas • Berkeley, California + 309 more

Conditions: Epidermolysis Bullosa Simplex, Pachyonychia Congenita
Interventions: Jojoba oil with broccoli sprout extract, Jojoba oil (placebo); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Melanoma
Interventions: Not listed
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Melanoma
Interventions: Electronic Health Record Review, Internet-Based Intervention, Patient Navigation, Survey Administration; Other · Behavioral
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma
Interventions: Everted suture technique, Non-everted suture technique; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Breast Cancer, Corpus Uteri Cancer, Ovary Cancer, Pancreas Cancer, Other Female Genital Malignant Neoplasms
Interventions: INSPIRE (INtegrating Systematic PatIent-Reported Evaluations), Capture of patient-reported outcomes, Enhanced Clinician Awareness; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 2,748 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Birmingham, Alabama • Los Angeles, California • Oklahoma City, Oklahoma

Conditions: Behcet Syndrome
Interventions: Tocilizumab; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriasis
Interventions: Skin biopsy, Blood draw; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer, Glioblastoma, Head and Neck Squamous Cell Carcinoma, Malignant Mesothelioma, Non-small Cell Lung Cancers, Sarcoma, Endometrial Cancer
Interventions: PRT3645; Drug
Lead sponsor: Prelude Therapeutics Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 12
States / cities: New Haven, Connecticut • Celebration, Florida • Miami, Florida + 8 more

Conditions: Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis From Malignant Melanoma of Skin (Disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis From Malignant Tumor of Bladder (Disorder)
Interventions: NBTXR3, SABR, Nivolumab, Pembrolizumab; Drug · Radiation
Lead sponsor: Nanobiotix; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 13
States / cities: San Francisco, California • Tampa, Florida • Atlanta, Georgia + 9 more

Conditions: Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue
Interventions: ADI PEG20, Ifosfamide, Radiotherapy, Mesna; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Psoriasis
Interventions: TSO 2500, TSO 7500; Drug
Lead sponsor: Mark Lebwohl; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Lymphoma, Hodgkin's Lymphoma
Interventions: surveys, Blood draw, Transvaginal ultrasounds; Behavioral · Other · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Melanoma
Interventions: CC-122, Nivolumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: Counseling session, Questionnaire 1, Questionnaire 2, online questionnaire; Behavioral · Other
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 35 Years to 120 Years · Female only
Enrollment: 1,023 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma (Skin)
Interventions: QS21, gp100 antigen, incomplete Freund's adjuvant, sargramostim, tyrosinase peptide; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors

CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris

A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis

Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients

L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer

Mirragen Diabetic Foot Ulcer Study

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin

In Vivo Real-time Detection of Circulating Melanoma Cells

Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor

Eversion in Dermatologic Surgery: Is Cosmetic Appearance Improved?

INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study

Tocilizumab for the Treatment of Behcet's Syndrome

Single Cell Genomics of Psoriatic Skin

A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma

Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma

Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer

Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma